The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Baseline visceral disease burden and treatment delivery factors association with outcomes after tumor-infiltrating lymphocyte therapy for metastatic melanoma.
 
Mohamed Aboelatta
No Relationships to Disclose
 
Jabra Zarka
No Relationships to Disclose
 
Nika Tchatchua
No Relationships to Disclose
 
Shahin Kavousi
No Relationships to Disclose
 
Jeffrey Johnson
Employment - CG Oncology (I)
Stock and Other Ownership Interests - CG Oncology (I)
Research Funding - Iovance Biotherapeutics (Inst)
Travel, Accommodations, Expenses - CG Oncology (I)
 
Deepti Behl
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Janssen Oncology; Lilly; Novartis
 
James Jakub
Consulting or Advisory Role - Breathe BioMedical; Clarix Imaging Corporation
 
Bently Doonan
Honoraria - Curis
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Curis; Immunocore; Pfizer; Replimune; Sun Pharma
Research Funding - Curis; Merck; Regeneron (Inst)
 
Mahesh Seetharam
Honoraria - AADi; Daiichi Sankyo; Deciphera; Horizon CME
Consulting or Advisory Role - SpringWorks Therapeutics
 
Lisa Kottschade
Consulting or Advisory Role - Immunocore; Replimune
Research Funding - Thermo Diagnostics (Inst)
 
Anastasios Dimou
Honoraria - Intellisphere; Intellisphere (Inst); Intellisphere (Inst); Roche/Genentech
Consulting or Advisory Role - Anheart Therapeutics; ChromaCode; Guardant Health (Inst); Nuvalent, Inc. (Inst); Rigel (Inst); TP Therapeutics (Inst)
Research Funding - Anheart Therapeutics (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Guardant Health; Janssen (Inst); Merck; Novartis (Inst); Philogen (Inst); Sorrento Therapeutics (Inst); Syntrix Biosystems (Inst)
Travel, Accommodations, Expenses - Guardant Health
Other Relationship - Rising Tide Foundation (Inst)
 
Matthew Block
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); nference (Inst); Perspective Therapeutics (Inst); Pharmacyclics (Inst); Regeneron (Inst); Sorrento Therapeutics (Inst); TILT Biotherapeutics (Inst); Transgene (Inst); Viewpoint Molecular Targeting (Inst)
Patents, Royalties, Other Intellectual Property - Combinations of Dendritic Cell-Based Vaccines and Checkpoint Inhibitors, patent pending (Inst); Dendritic Cell-Based Vaccines and Uses Thereof, patent pending (Inst)
(OPTIONAL) Uncompensated Relationships - Sorrento Therapeutics; TILT Biotherapeutics; Viewpoint Molecular Targeting
 
Heather Montane
No Relationships to Disclose
 
Tina Hieken
Research Funding - Genentech/Roche (Inst); Skyline Diagnostics (Inst)
 
Svetomir Markovic
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Nanoparticles (patents); Nanoparticles - immunoconjugates
 
Arkadiusz Dudek
Leadership - TTC Oncology
Stock and Other Ownership Interests - IGF Oncology; TTC Oncology
Consulting or Advisory Role - HiberCell; Iovance Biotherapeutics
Research Funding - IDEAYA Biosciences (Inst); Immunocore (Inst); Replimune (Inst)
Patents, Royalties, Other Intellectual Property - IGF Oncology